Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Stable plaque psoriasis, duration \> 1 year.~2. Patients with Chinese medicine blood stasis syndrome. (2)18 to 65 years old, male or female patient.~3. Mild psoriasis:3\<PASI≤10, and BSA≤10%.~4. Informed consent.~Exclusion Criteria:~1. Guttate psoriasis, inverse psoriasis or exclusively involves the face;~2. Acute progression of psoriasis, and erythroderma tendency.Not blood stasis syndrome.Not stable psoriasis.~3. Pregnant, lactating, or which one plan to become pregnant in a year;~4. SAS（Self-rating Anxiety Scale）\> 50 or SDS（Self-rating Depression Scale）\> 53, or with other psychiatric disorders;~5. With history of cardiovascular, respiratory, digestive, urinary, and hematologic disease, which can't controlled through common treatment. Either with cancer, infection, electrolyte imbalance, acid-base disturbance and calcium metabolic disorder.~6. Allergic to any medicine or ingredients used in this study.~7. Participating other clinical trials or participated within 1 month.~8. Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks.~9. Patients need systemic treatment prescribed by doctors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PSORI-CM01（YXBCM01）granule (Type: EXPERIMENTAL): PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
- PSORI-CM01（YXBCM01）granule low dose group (Type: EXPERIMENTAL): PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
- placebo (Type: PLACEBO_COMPARATOR): Placebo granule 1.1g os once a day for 12weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).